RxDoctor Payments Data

Nathan Lambert, MD

Cardiovascular Disease · Fishers, INNPI 1356361018

Payments from drug & device makers

$3,804in general payments, 2019–2025

Across 77 payments — averaging $49.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$3K
  • Cardiovascular Systems Inc.$178
  • Acist Medical Systems, Inc.$117
  • Lantheus Medical Imaging, Inc.$104
  • Abbott$89
  • Shockwave Medical, Inc$85
  • plus $252 from 8 others

What the payments were for

  • Travel & lodging$2,22959%
  • Food & beverage$1,57541%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,804 in reported general payments places this provider in the 50th percentile of 408 cardiovascular disease providers in Indiana.

See all cardiovascular disease providers in Indiana

Medicare billing

Part B allowed, 2024
$232,392
Medicare patients
1,509
Services billed
5,078

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban527$663,783
GalafoldMigalastat Hcl11$335,363
Repatha SureclickEvolocumab132$146,424
EntrestoSacubitril/Valsartan73$81,254
XareltoRivaroxaban71$71,016
Praluent PenAlirocumab77$57,420
JardianceEmpagliflozin18$25,788
FarxigaDapagliflozin Propanediol22$25,626
MounjaroTirzepatide13$25,287
BrilintaTicagrelor17$15,292
Ranolazine ErRanolazine77$9,977
Atorvastatin Calcium637$9,750
Metoprolol Succinate563$8,356
Dabigatran EtexilateDabigatran Etexilate Mesylate20$7,168
Prasugrel Hcl40$6,325

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Brilinta$12$40,91839 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 408 cardiovascular disease providers in Indiana.

Other cardiovascular disease in Fishers

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →